ASCO: Avastin Improves Survival in Advanced Cervical Cancer
Results from the phase III GOG 240 trial, presented at ASCO, showed the addition of bevacizumab (Avastin) to standard chemotherapy improved overall survival by nearly 4 months in women with advanced or relapsed cervical cancer. (Source: Cancer Network)
Source: Cancer Network - June 7, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Vinegar Screening Significantly Reduces Cervical Cancer Mortality
Biennial visual inspection with acetic acid (vinegar) screening by trained public health workers significantly reduced cervical cancer mortality in a large cluster-randomized controlled trial conducted among thousands of women from poor neighborhoods in Mumbai, India. (Source: Cancer Network)
Source: Cancer Network - June 7, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy by Subtype
In a study presented at ASCO, a team of researchers used microarrays to characterize 130 triple-negative breast cancer patients treated with neoadjuvant chemotherapy to see whether certain subtypes are more likely to respond to the treatment. (Source: Cancer Network)
Source: Cancer Network - June 7, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Frequent Genetic Mutations in Black Women With Breast Cancer
A single-center study analyzed the frequency of breast cancer susceptibility mutations among black women diagnosed with breast cancer. The findings suggest that broader genetic screening may be beneficial for these women. The study also suggests that family history is not the only criteria by which patients at risk for breast cancer can be identified. (Source: Cancer Network)
Source: Cancer Network - June 7, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Updated Analyses Confirm Safety and Efficacy of Ra-223 in CRPC
Further analyses of data subsets from the ALSYMPCA study of the alpha particle-emitting isotope Ra-223 (Xofigo) were presented at ASCO, providing additional evidence of efficacy and safety of the recently FDA approved therapeutic agent. (Source: Cancer Network)
Source: Cancer Network - June 6, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Pemetrexed Plus Carboplatin No Better Than Bevacizumab-Containing Regimen in NSCLC
A phase III study, presented at ASCO, comparing pemetrexed and carboplatin with paclitaxel, carboplatin, and bevacizumab failed to find a difference in a composite endpoint of progression-free survival and severe drug-related toxicities in patients with nonsquamous non–small-cell lung cancer. (Source: Cancer Network)
Source: Cancer Network - June 6, 2013 Category: Cancer & Oncology Source Type: news

Proteomic Stratification Test Can Help Guide Second-Line Treatment of NSCLC
A simple serum protein test can help guide treatment decisions between chemotherapy and erlotinib as second-line therapy for patients with non-small-cell lung cancer, according to results of a phase III study presented at ASCO. (Source: Cancer Network)
Source: Cancer Network - June 6, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Heat Shock Protein 90 Inhibitor Shows Promise in NSCLC
Results from the GALAXY-1 trial showed that the novel second-generation heat shock protein 90 (HSP90) inhibitor ganetespib could potentially improve survival in patients with advanced-stage non–small-cell lung cancer. (Source: Cancer Network)
Source: Cancer Network - June 6, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Immunotherapy for Advanced Melanoma
Building on the landmark studies of the immunotherapeutic agent ipilimumab just a few years back, ASCO 2013 saw the presentation of truly impressive data on two PD1 blockers, as well as noteworthy studies of other immunotherapeutic approaches to advanced melanoma. (Source: Cancer Network)
Source: Cancer Network - June 6, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Fewer Toxicities With Weekly Adjuvant Paclitaxel in Breast Cancer
A phase III trial presented at ASCO showed similar efficacy between two adjuvant paclitaxel regimens, but the weekly regimen led to fewer patient side effects. (Source: Cancer Network)
Source: Cancer Network - June 6, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Adding Curcuminoids to Docetaxel Shows Promise in Castration-Resistant Prostate Cancer
Addition of curcuminoids to treatment with docetaxel was well tolerated and showed promise in improving the response rate to docetaxel “in terms of both PSA decrease and objective response” in a phase II trial in patients with castration-resistant prostate cancer. (Source: Cancer Network)
Source: Cancer Network - June 5, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Fewer Side Effects With Radiotherapy Alone for Some Node-Positive Breast Cancer Patients
A study presented at ASCO shows that axillary radiotherapy results in similar outcomes to axillary lymph node dissection, but halved the incidence of lymphedema. (Source: Cancer Network)
Source: Cancer Network - June 5, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Rapid, Durable Bone Met Pain Relief With MR Guided Focused Ultrasound
The use of magnetic resonance guided focused ultrasound ablation therapy for the management of painful bone metastases resulted in a high rate of pain response that was rapid, durable and clinically meaningful, according to an abstract presented at the 2013 ASCO Annual Meeting in Chicago. (Source: Cancer Network)
Source: Cancer Network - June 4, 2013 Category: Cancer & Oncology Source Type: news

ASCO: NSCLC Tumor Profiling and Biomarker-Guided Therapy are Feasible
A massive French database study shows that genetic tumor profiling in patients with non–small-cell lung cancer (NSCLC) is feasible, and is already helping physicians guide treatment in many patients, according to results presented at the American Society of Clinical Oncology annual meeting. (Source: Cancer Network)
Source: Cancer Network - June 4, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Enzalutamide Monotherapy in Prostate Cancer Achieves ‘High Response Rate, Marked PSA Decline'
Monotherapy with enzalutamide (Xtandi) achieved a “high PSA response rate and marked PSA decline” in patients with hormone-naïve prostate cancer after 6 months in a single-arm, multicenter phase II study. (Source: Cancer Network)
Source: Cancer Network - June 4, 2013 Category: Cancer & Oncology Source Type: news